



PATENT

Case Docket No. ABGENIX.071A

Date: March 1, 2004


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Owens, et al.
Appl. No. : 10/725,962
Filed : December 2, 2003
For : ANTIBODIES AGAINST
DRUGS OF ABUSE
Examiner : Unassigned
Group Art Unit : 1635

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 1, 2004

(Date)


Erik T. Anderson, Reg. No. 52,559

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with ten (10) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.



Erik T. Anderson
Registration No. 52,559
Attorney of Record
Customer No. 20,995
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicant	:	Owens, et al.
App. No.	:	10/725,962
Filed	:	December 2, 2003
For	:	ANTIBODIES AGAINST DRUGS OF ABUSE
Examiner	:	Unassigned
Group Art Unit	:	1635

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing ten (10) references that are also enclosed.

This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 3/1/04

By: 

Erik T. Anderson
Registration No. 52,559
Attorney of Record
Customer No. 20,995

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.071AAPPLICATION NO.
10/725,962INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Owens, et al.FILING DATE
December 2, 2003GROUP
1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	2001/0051158 A1	12/13/01	Owens, et al.			
	2	2003/0171435 A1	09/11/03	Pouletty, et al.			
	3	6,669,937 B2	12/30/03	Owens, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	4	EP 1 331 219 A1	07/30/03	EUROPE			X	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	5	Davis, et al., "A simple modified carbodiimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking", Analytical Biochemistry, vol. 116, pp. 402-407, (1981).
	6	Owens, et al., "Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor", The Journal of Pharmacology and Experimental Therapeutics, vol. 246, no. 2, pp. 472-478, (1988).
	7	McClurkan, et al., "Disposition of a monoclonal anti-phencyclidine fab fragment of immunoglobulin G in rats", The Journal of Pharmacology and Experimental Therapeutics, vol. 266, no. 3, pp. 1439-1445, (1993).
	8	Valentine, et al., "Anti-phencyclidine monoclonal fab fragments markedly alter phencyclidine pharmacokinetics in rats", The Journal of Pharmacology and Experimental Therapeutics, vol. 269, no. 3, pp. 1079-1085, (1994).
	9	Valentine, et al., "Antiphencyclidine monoclonal fab fragments reverse phencyclidine-induced behavior effects and ataxia in rats" The Journal of Pharmacology and Experimental Therapeutics, vol. 278, no. 2, pp. 709-716, (1996).
	10	Valentine, et al., "Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats", The Journal of Pharmacology and Experimental Therapeutics, vol. 278, no. 2, pp. 717-724, (1996).

S:\DOCS\ETA\ETA-2026.DOC/cfg/030104

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	